On June 18, 2024, the GB Sciences, Inc. (the Company) and EndoPure Life Sciences, LLC (EndoPure) entered into a non-legally binding letter of intent to negotiate and enter into a license agreement . Pursuant to the Agreement EndoPure will license certain intellectual property rights (the IP) from within the intellectual property portfolio of the Company and develop, manufacture, and market pharmaceutical products (the Products or a Product) that are protected within the Company?s IP portfolio. After EndoPure has successfully developed a Product and obtained certain regulatory approvals to market the Product in Brazil, EndoPure will be given exclusive rights to market the Product in South America.

The Company will receive a royalty equal to 5% of the gross sales of Products sold by EndoPure and certain other considerations. The Company and EndoPure agree to diligently prepare and execute the Agreement by July 17, 2024.